Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

Abstract

Anti-ICAM-1 MAb therapy was well tolerated, resulted in a transient alteration in T lymphocyte recirculation, and effected clinical improvement in some RA patients.